Olanzapine Induces Insulin Resistance: Results From A Prospective Study
J Clin Psychiatry 2003;64(12):1436-1439
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The aim of this study was to compare
glucose metabolism in patients with schizophrenia receiving
olanzapine with that in control subjects.
Method: We conducted a prospective, controlled,
open study comparing body weight, fat mass, and indices of
insulin resistance/sensitivity in 10 olanzapine-treated patients
with ICD-10 schizophrenia (olanzapine dose range, 7.5-20 mg/day)
with those of a group of 10 mentally and physically healthy
volunteers. Weight, fat mass, and indices of insulin
resistance/sensitivity were assessed over individual 8-week
observation periods from November 1997 to October 1999.
Results: Fasting serum glucose and fasting serum
insulin increased significantly in the olanzapine-treated
patients (p = .008 for glucose and p = .006 for insulin). The
homeostasis model assessment (HOMA) index for beta cell function
did not change significantly in the olanzapine-treated patients,
whereas the HOMA index for insulin resistance did increase (p =
.006). In the control group, these parameters were stable. A
significant increase in body weight (p = .001) and body fat (p =
.004) was seen in patients treated with olanzapine, while the
control group showed no significant changes.
Conclusion: This study indicates that the
disturbances in glucose homeostasis during antipsychotic
treatment with olanzapine are mainly due to insulin resistance.
However, beta cell function remains unaltered in
olanzapine-treated patients. We conclude that treatment with some
second-generation antipsychotic drugs may lead to insulin